Serotonin Control of Impulsivity in Tourette Disorder

NCT05942716 | Recruiting Phase 2

• 1 other identifier: 69HCL22_0683
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 2

Brief Summary

Tourette disorder (TD) is a neurodevelopmental disorder characterized by motor and vocal tics. It is often associated with multiple psychiatric comorbidities involving a high degree of impulsivity such as obsessive-compulsive disorders (OCD), attention-deficit hyperactivity disorders (ADHD), and intermittent explosive disorders (IED). Although a substantial body of clinical studies have emphasized the role of the dopamine system in motor symptoms, little is known about how the serotonergic (5-HT) system modulate both cognitive and affective abilities in TD. Several lines of evidence suggest that different 5-HT receptor subtypes may constitute a crucial factor in the development and maintenance of different symptoms. Because abnormal 5-HT2A receptor bindings have been reported in patients with TD and aripiprazole (drug of first choice) is a 5-HT2A antagonist, we hypothesize that 5-HT2A receptors may play an important role in regulating psychiatric symptoms in TD such as those characterized by impulsive behaviors. To investigate the involvement of 5-HT2A receptors in TD, we propose to perform a multimodal imaging study with 20 adult patients (ON and OFF treatment). Neuroimaging data will be collected with a hybrid system that simultaneously combines the positron emission tomography (PET) and the functional magnetic resonance imaging (fMRI). A highly selective PET radiotracer (\[18F\]-altanserin) will map 5-HT2A receptor bindings in the whole brain, while fMRI will provide detail information regarding the altered brain activities.

Conditions

Tourette Disorder

Keywords

Tourette; Serotonin; Impulsivity; Neuroimaging

Outcome Measures

Primary Outcomes (1)

• Correlation coefficients between receptor-specific imaging data (PET) and scores of impulsivity measured by the Barratt scale (BIS11).

  Correlation coefficients between changes in the binding potential (BPND) of \[18F\]-altanserin measured voxel-by-voxel in the whole brain and the evolution of scores BIS11 in TD patients.

  As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.

Secondary Outcomes (3)

• Correlation coefficients between receptor-specific imaging data (PET) and other clinical/behavioral scores.

  As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.

• Correlation coefficients between functional imaging data (fMRI) and scores of impulsivity measured by the Barratt scale (BIS11).

  As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.

• Correlation coefficients between functional imaging data (fMRI) and other clinical/behavioral scores.

  As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.

Study Arms (1)

Tourette disorder

EXPERIMENTAL

25 mixt adult patients with TD. Patients will be recruited if a current treatment by aripiprazole (5-15 mg) is already scheduled before the study.

Drug: Administration of a PET radiotracer

Interventions

Administration of a PET radiotracer DRUG

A highly selective 5-HT2A receptor ligand (\[18F\]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine. Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic.

Tourette disorder

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or Female
• Diagnosed with a Tourette Disorder following the DSM-5
• Age between 18-65 years
• Member of a social security scheme in France
• Freely-given informed consent to participate to this study (written form)
• With a current treatment by aripiprazole already scheduled
• With Tics compatible with TEP/fMRI exams
• Having (for women only) effective contraception throughout participation in the study.

You may not qualify if:

• Male or Female
• A serious not controlled psychiatric comorbidity
• A serious, evolving or debilitating pathology with a potential influence on the study
• Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin)
• Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia)
• Women breastfeeding
• Protected or restricted person (administratively or in judicial terms)
• Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study
• Do not speak french

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (2)

Service de neurologie C Hôpital neurologique Pierre Wertheimer/GHE Hospices Civils de Lyon

Bron, 69677, France

RECRUITING

Centre de Référence Syndrome Gilles de la Tourette Département de Neurologie Pôle des Maladies du Système Nerveux Hôpital de la Pitié-Salpêtrière

Paris, 75013, France

NOT YET RECRUITING

MeSH Terms

Conditions

Tourette Syndrome; Impulsive Behavior

Condition Hierarchy (Ancestors)

Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tic Disorders; Movement Disorders; Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neurodevelopmental Disorders; Mental Disorders; Behavior

Central Study Contacts

Benjamin PASQUEREAU

CONTACT

+33 437 911 241; benjamin.pasquereau@isc.cnrs.fr

Stephane THOBOIS

CONTACT

+33 472 357 222; stephane.thobois@chu-lyon.fr

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 4, 2023
• First Posted: July 12, 2023
• Study Start: September 24, 2024
• Primary Completion (Estimated): September 24, 2027
• Study Completion (Estimated): September 24, 2028
• Last Updated: December 4, 2024

Record last verified: 2024-12

Locations

FR (2)